Clinical Trials · us
68% Lower Risk of Bladder Cancer Recurrence After Surgery: Phase 3 Cretostimogene Trial Meets Primary Endpoint
How can the time without recurrence be extended after tumor removal? A randomized trial involving 367 patients provides positive evidence for an intravesical oncolytic virus therapy, but its advantage over surveillance does not yet establish whether it is superior to other postoperative treatments.
For patients with non–muscle-invasive bladder cancer, recurrence after removal of the existing tumor may mean facing examinations and surgery again. On November 16, CG Oncology announced that its investigational drug cretostimogene met the primary endpoint in the Phase 3 PIVOT-006 trial: treatment after complete tumor removal reduced the risk of recurrence by 68% compared with surveillance alone. The result provides new evidence for extending the time without recurrence after surgery.
According to the company announcement and materials filed with the U.S. Securities and Exchange Commission, the hazard ratio for recurrence was 0.32, with a 95% confidence interval of 0.23 to 0.45 and a p-value below 0.0001. At the October 26, 2026 data cutoff, median follow-up was 17 months. The “68% reduction” reflects a relative comparison of recurrence risk during follow-up. It does not mean that 68 fewer patients out of every 100 experienced recurrence, nor can it be interpreted as a 68-percentage-point increase in the cure rate.
PIVOT-006 enrolled 367 patients at approximately 90 centers in the United States and Canada, randomly assigning them in a one-to-one ratio to cretostimogene or surveillance in an open-label design. Urology Times noted that eligibility encompassed several intermediate-risk disease types, including some recurrent, multiple, or larger low-grade tumors, as well as solitary high-grade Ta tumors no more than 3 centimeters in diameter; high-grade T1 tumors and carcinoma in situ were excluded. The findings therefore have a defined scope of applicability and cannot be directly generalized to all patients with bladder cancer.
Cretostimogene is an investigational oncolytic virus immunotherapy administered by intravesical instillation. The treatment group first received an induction course, followed, if no recurrence occurred, by quarterly maintenance courses through month 13. Both groups were monitored with cystoscopy and urine cytology, with resection or biopsy for confirmation when necessary. Targeted Oncology also noted that patients in the surveillance group could be offered cretostimogene treatment if recurrence occurred. This design primarily addresses whether adding the drug after surgery can delay recurrence; it has not directly compared its effects with those of other active postoperative therapies.
Regarding safety, the company said that, as of the data cutoff, there had been no Grade 3 or higher treatment-related adverse events and no discontinuations due to treatment-related issues. This is a positive signal, but it does not mean there were no side effects at all. The information released so far remains a summary of the trial’s primary results. More detailed data are still needed to assess the full distribution of adverse events, differences in efficacy across disease types, and longer-term disease progression. An improvement in recurrence-free survival also cannot be directly equated with longer overall survival.
CG Oncology plans to present the results at the Society of Urologic Oncology annual meeting on December 2 and to submit a biologics license application using PIVOT-006 data in the second quarter of 2027. A separate application for patients whose disease is unresponsive to bacillus Calmette–Guérin (BCG) treatment, covering a broader range of disease types, is expected to be completed in March 2027. These are separate application timelines. For this therapy, which has not yet been approved, the next key questions are whether the full data can support sustained and clinically meaningful control of recurrence, and how regulators ultimately define the eligible patient population.